mc-4

MC4 is a first-in-class inhibitor of ribosomal RNA synthesis with antimicrobial activity against Staphylococcus aureus.

PF-07258669 is a selective melanocortin 4 receptor (MC4) antagonist used in the study of cachexia and loss of appetite.

DLIN-MC4-DMA is a lipid membrane and is a potential nucleic acid carrier.

Beta-MSH (1-22) (human) acetate (Beta-MSH (1-22) (human) acetate (17908-57-5 Free base)) , is an endogenous melanocortin-4 receptor (MC4-R) agonist.

MC4-NN2-0453 is an α-MSH analog and a selective MC4R agonist. This compound is utilized in studies related to obesity research.

MC-4R Agonist 1 is an agonist of the human melanocortin-4 receptor (MC-4R) and is useful in researching sexual dysfunction, obesity, and diabetes.

RMC-4550 is an effective and allosteric inhibitor of SHP2 (IC50: 0.583 nM).

UAMC-4821 is a ferroptosis inhibitor with an IC50 of 5.2 nM. It effectively scavenges free radicals, inhibits lipid peroxidation, and prevents ML162-induced ferroptosis, providing protective effects on HT-1080 cells. With favorable pharmacokinetic properties in mice, UAMC-4821 presents an oral bioavailability of 63% and demonstrates blood-brain barrier permeability.

RMC-4998 formic is an orally active inhibitor targeting the GTP-bound state of the KRASG12C mutant. It forms a trimeric complex with intracellular CYPA and the activated KRASG12C mutant, displaying an IC50 value of 28 nM. This compound inhibits ERK signaling and induces apoptosis in KRASG12C mutant cancer cells and is utilized in tumor research.

IMC-48, as a BCL2 i-motif-interactive compound, can act by stabilizing or facilitating the folding of the i-motif.

RMC-4630 (SHP2-IN-7) is an inhibitor of SHP2.

RMC-4529 is a chemical compound that demonstrates potent inhibition, with an IC50 value of 1.0 nM, against p-4E-BP1-(T37/46) in mTOR kinase cellular assays.

RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.

RMC-4998 is an orally available KRASG12C mutant inhibitor that targets the active or GTP-bound state of the KRASG12C mutant and binds to intracellular CYPA to form a triple complex to inhibit the ERK signaling pathway and induce apoptosis, which is of great significance for tumor research.

Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor PF-06651600 led to its evaluation in several human clinical studies. JAK3 was among the first of the JAKs targeted for therapeutic intervention due to the strong validation provided by human SCID patients displaying JAK3 deficiencies.

Dersimelagon (MT-7117) is an orally active, selective melanocortin 1 receptor (MC1R) agonist with EC50 values ​​of 8.16, 3.91, 1.14, and 0.251 nM for human (h), cynomolgus monkey (cm), mouse (m), and rat (r) MC1R, respectively. Dersimelagon exhibits good affinity for hMC1R and hMC4R, with Ki values ​​of 2.26 and 32.9 nM, respectively. Dersimelagon can be used in the study of skin pigmentation[1].

Bivamelagon hydrochloride is a selective MC4R agonist (EC50=36.5 nM, Ki=65 nM) with the advantages of oral available and blood-brain barrier penetration, suitable for obesity and diabetes research.

1-Naphthyl 3,5-dinitrobenzoate (JMC-4) is an inhibitor of 5-LOX can be used in studies about inflammatory therapy.

[D-Trp8]-γ-MSH acetate(321351-81-9 free base) is a selective melanocortin 3 (MC3) receptor agonist (IC50 values are 6.7, 340 and 600 nM for human MC3, MC5 and MC4 receptors respectively) and displays anti-inflammatory efficacy.

SNT-207707 is a potent, selective and orally active antagonist of melanocortin MC-4 receptor(IC50 of 8 nM (binding) and 5 nM (function) on the MC-4 receptor).

SNT-207858 free base is a selective, blood brain barrier penetrating, potent and orally active antagonist of melanocortin-4 (MC-4) receptor(IC50 of 22 nM (binding) and 11 nM (function), on the MC-4 receptor).

SNT-207858 is a selective, blood brain barrier penetrating, potent and orally active antagonist of melanocortin-4 (MC-4) receptor. SNT207858 has an IC50 of 22 nM (binding) and 11 nM (function) on the MC-4 receptor.

Adrenocorticotropic Hormone (ACTH) (4-10), human is a potent agonist of the melanocortin receptor (MC4R).

Bivamelagon (LB54640) is an orally effective MC4R (melanocortin 4) agonist with the advantage of crossing the blood-brain barrier, suitable for studying hypothalamic obesity and diabetes.